Episode 198 - October 2, 2026

What It Covers

Biotech Hangout Episode 198 covers Q3 2026 biotech market performance with XBI up 27% year-to-date, major BD deals including Regeneron-Sanofi's $8B INI collaboration and AstraZeneca's $2B Summit equity investment, FDA approvals for FOP and Parkinson's treatments, and clinical data from WCLC and EASD conferences covering lung cancer and GLP-1 obesity therapies.

Key Questions Answered

• •XBI Sector Divergence: The XBI's 27% YTD gain masks severe underlying dispersion — heavily shorted, under-owned names like Moderna, Iovance, and Summit propped up the index while broadly held specialist fund positions declined sharply. Investors should monitor Morgan Stanley prime broker dispersion data to distinguish index-level performance from actual portfolio exposure, as the two have diverged significantly since late August's $169 XBI peak.
• •Dupixent Patent Extension: Sanofi's CFO signaled the Dupixent composition-of-matter patent could extend from 2031 to approximately late 2037, aligning with independent patent analysis. Investors tracking IL-4/IL-13 pathway assets should factor this extended runway into LOE modeling. The Regeneron-Sanofi deal adds four next-generation antibodies — including an IL-13 lead, a bispecific, a "super dupey," and a long-acting IL-4 — targeting less frequent dosing to preempt biosimilar competition.
• •Summit-AstraZeneca Deal Structure: AstraZeneca's $2B equity stake at a premium in Summit Therapeutics represents a novel deal structure where the strategic partner co-funds R&D trials — a structure rarely seen in PD-1/VEGF collaborations. Investors should watch the Harmony 3 trial readout on vunicimab for PFS data with a directional OS signal; an "immature OS" comment at readout would likely be interpreted negatively by the market.
• •GLP-1 Weight Loss Benchmarks: Lilly's retatrutide (GLP-1/GIP/glucagon triple agonist) achieved 21% weight loss in diabetic patients at 80 weeks in the TRIUMF-2 trial, crossing a threshold considered difficult in this population. A separate tirzepatide-amylin combination showed 23.3% weight loss at 48 weeks but carried a 27% discontinuation rate versus 3% for tirzepatide alone — a safety signal that regulators and competitors developing combination obesity therapies should weigh carefully.
• •Gene Therapy Durability Risk: Unicure's Huntington's disease gene therapy AMT-130 showed disease progression slowing drop from 75% at the prior update to 44% at four years, sending shares down 37% in a single session. Investors evaluating gene therapy assets should stress-test durability assumptions across multi-year follow-up periods, as early efficacy signals in phase 1/2 studies may not hold, particularly in CNS indications where delivery and expression consistency remain unresolved challenges.
• •China Biotech Deal Velocity: Three China-originated biotech deals closed in one week: Novo Nordisk paid $300M upfront plus $2.6B for Henri's GLP-1/GIP bispecific, Merck paid $400M upfront plus $2.13B for Cybranch's oral KRAS G12D inhibitor, and Novartis paid $575M upfront plus $7.2B for Avogene's mRNA CD19/CD3 T-cell engager. Investors tracking oncology and metabolic disease pipelines should monitor Chinese biotechs as a consistent source of late-stage licensing targets.